Navigation Links
BioMarin Announces Second Quarter 2011 Financial Results

and Amortization (EBITDA) adjusted to exclude non-cash stock compensation expense, contingent consideration expense and certain nonrecurring material items (adjusted EBITDA).  

The following tables detail the reconciliation of non-GAAP to GAAP financial metrics:

Reconciliation of GAAP Net Income (Loss) to Non-GAAP Adjusted EBITDA(in millions)(unaudited)Three Months EndedJune 30, Six Months EndedJune 30, Year EndingDecember 31, 2011 NOTES2011201020112010Guidance GAAP Net Income (Loss)$ (5.1)$ (0.5)$ (9.4)$   0.7 $(43) - $(33) Interest expense, net1.3




6Income tax expense3.9












4EBITDA 7.47.516.514.6 6 - 16 Stock-based compensation10.6




45Gain on sale of equity investments-(0.9)

-Contingent consideration






(2)Adjusted EBITDA$ 13.9$ 17.5$ 32.9$ 32.9 $49 - $59 (1)  Represents the changes in the fair value of contingent acquisition consideration payable for the period.   BioMarin believes that this non-GAAP information is useful to investors, taken in conjunction with BioMarin's GAAP information because it provides additional information regarding the performance of BioMarin's core ongoing business, Naglazyme, Kuvan, Aldurazyme and Firdapse and development of its pipeline.  By providing information about both the overall GAAP financial performance and the non-GAAP measures that focus on continuing operations, the company believes that the additional information enhances investors' overall understanding of the company's business and prospects for the future.  Further, the company uses both the GAAP and the non-GAAP results and expectations internally for its operating, budgeting and financial planning purposes and uses th

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. BioMarin Announces FDA Approval for Kuvan
3. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
5. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
7. BioMarin Acquires Huxley Pharmaceuticals, Inc.
8. BioMarin to Present at the Oppenheimer Healthcare Conference
9. BioMarin Announces Third Quarter 2009 Financial Results
10. BioMarin to Acquire LEAD Therapeutics
11. BioMarin to Present at the Credit Suisse Healthcare Conference
Post Your Comments:
(Date:7/22/2014)... ST. LOUIS , July 22, 2014  According ... the time their children spend on digital devices. An ... the ages of 10 and 17 estimate they use ... day. However, a separate AOA survey of parents revealed ... use an electronic device for that same amount of ...
(Date:7/22/2014)... July 22, 2014  Vernalis plc (LSE: VER) and Tris ... (POC) for CCP-08, the third programme to achieve ... collaboration. Under this collaboration, POC requires the successful ... pilot comparative study against an immediate release reference ... will make a milestone payment to Tris. ...
(Date:7/22/2014)... PORT WASHINGTON, New York , ... Neue Partnerschaft für umfassenden ... gefährlichen Medikamenteneinwirkungen in Österreich    ... führender Anbieter von geschlossenen Transfersystemen (Closed System ... Medikus , einen Vertriebshändler und ...
Breaking Medicine Technology:Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 3Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 4Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 2Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 3Equashield ernennt Medikus zu seinem exklusiven österreichischen Vertriebspartner für seine geschlossenen Arzneimitteltransfersysteme 2
(Date:7/22/2014)... 2014 Cloud+MD Office 2.0 ... suite of medical software and services, designed by ... that produces “Actionable Information” to help Independent Physician ... and Billing Services optimize a wide range of ... Greater Efficiency, Noticeable Cost Reductions and Better Patient ...
(Date:7/22/2014)... For the past nine years, the ... working in tandem to help thousands of cancer patients ... care, and help survivors connect to resources dealing with ... their partnership to include referrals from PAF to LIVESTRONG ... other practical, emotional, and financial issues that accompany a ...
(Date:7/22/2014)... Joining Conquer Paralysis Now as its first champion in ... Paralympic silver medalist and quadriplegic Jennifer French. , As a ... a spinal cord injury in 1998. Now, she has joined ... , “People define cure differently,” French said. “For some, it’s ... the image in our minds of what we were like ...
(Date:7/22/2014)... July 22, 2014 Altec Products, ... workflow solutions, announced today their Gold Sponsorship of ... at Mandalay Bay Hotel and Casino in Las Vegas, ... Summit draws thousands interested in taking advantage of the ... to solve business problems and educate themselves on the ...
(Date:7/22/2014)... Bramal LED announced that they will be ... Jr, airing later this year via Discovery Channel. Dates and ... about Bramal LED’s T-10 lamps, which provide over 80,000 hours ... to 70 percent. Bramal LED’s T-10 lamps can be plugged ... or on direct AC voltage, with no need for an ...
Breaking Medicine News(10 mins):Health News:Cloud-MD Software will soon Receive MU2 Certification 2Health News:LIVESTRONG Foundation and Patient Advocate Foundation Expand Partnership to Support the Needs of Cancer Patients and Survivors Nationwide 2Health News:LIVESTRONG Foundation and Patient Advocate Foundation Expand Partnership to Support the Needs of Cancer Patients and Survivors Nationwide 3Health News:Paralympian Jen French Announced as Conquer Paralysis Now’s First Champion 2Health News:Altec Announces Gold Sponsorship of Sage Summit 2014 2Health News:Altec Announces Gold Sponsorship of Sage Summit 2014 3Health News:Bramal LED to be featured in Upcoming Episode of Innovations with Ed Begley, Jr. 2
... joint becomes inflamed. Treatment is often difficult and recovery ... the pain of this common condition. ,Now, an ... with extracorporeal shock wave therapy. During the therapy, ultrasound ... takes two to three 20-minute shock wave treatments to ...
... located at the base of the hair follicle. Hair ... In many people with hair loss, however, // the ... of abnormal follicles entering longer resting phases and producing ... University of Pennsylvania School of Medicine have isolated stem ...
... say there could be a new way to help prevent ... // increase high-density lipoprotein levels, also known as good cholesterol. ... for heart disease. They are commonly used to lower low-density ... target is a low level of good cholesterol. In fact, ...
... Toronto conducted a study to examine whether current procedures ... antibiotics // unnecessarily. Out of an estimated 6.7 million ... Doctors also researched the use of throat cultures and ... who were prompted to seek medical help for their ...
... attention deficit/hyperactivity disorder (ADHD) affects up to 12 percent of ... increased attention problems at age 7 among kids was seen ... toddlers.The study tracked the number of hours kids watched television ... two hours of television a day. Three-year-olds watched about three ...
... warnings from the Food and Drug Administration may leave ... what they claim.// ,Some of the products ... Blocker, and Zone Fat Blocker.Many of these supplements claim ... consumers to lose weight without making any lifestyle changes. ...
Cached Medicine News:
Long handle occluder - Black...
Double Ended Occluders...
Double Ended Occluders...
Designed to provide occlusion while permitting observation of the eye. Helpful to determine if only one eye is deviating. Approximately 9 inches long....
Medicine Products: